Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-lesional Nivolumab for Limited Cutaneous Kaposi Sarcoma
NCT03316274Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- May 2018
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in Kaposi sarcoma (KS) (3 cohorts), sponsored by University of California, San Francisco. Primary endpoints: Dose Limiting Toxicities at 6 months and Maximum Tolerated Dose at 6 months. Started May 2018; status: completed.
02
Drugs
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT03316274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316274.